Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Pyroptosis-inducible Newcasstle Disease Oncolytic Virus (PIN) Plus Sintilimab (Anti-PD1 Antibody) for Patients With Advanced pMMR/ MSS Colorectal Cancer With Hepatic Metastases:an Open-Label, Randomized,Phase I Study.

NCT07411781 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07411781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07411781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Pyroptosis-inducible Newcasstle Disease Oncolytic Virus (PIN) Plus Sintilimab (Anti-PD1 Antibody) for Patients With Advanced pMMR/ MSS Colorectal Cancer With Hepatic Metastases:an Open-Label, Randomized,Phase I Study.
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
March 1, 2031
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult, colorectal cancer